Skip to content
DataLookout
Menu

NCT07123519

A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases

StatusRecruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Aug 13, 2026 to Aug 13, 2027 Show 4 more changesShow less
    • Eligibility criteria expanded, about 26 words
    • Secondary endpoints: details revised at 1 of 6 entries
    • Site details revised
    • Collaborators: details revised at 1 of 1 entry
  2. Notable Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v3
  3. Notable Eligibility criteria expanded, about 11 wordsv2
  4. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Incidence of Treatment-Emergent Adverse Events
Timeframe: The efficacy endpoint evaluation for 2, 4, 8, 12 weeks, AEs observation will be follow-up for 24 weeks. The observation period is extended to 52 weeks.

Secondary (6)

Efficacy Evaluation in relapsed/refractory autoimmune diseases
Maximum Plasma Concentration of YTS109 (Cmax)
Area Under the Plasma Concentration-Time Curve (AUC) of YTS109
Time to Reach Maximum Plasma Concentration (Tmax) of YTS109
Cytokines Concentration Level Change
Show 1 moreShow less
The reconstitution of B cell in peripheral blood

Arms and interventions

YTS109 cellExperimental

Subjects will receive YTS109 cell once in this study.

Drugs: YTS109 cell

Sites

1 site in 1 country

  • Institute of Hematology & Blood Diseases Hospital, ChinaTianjin, China